Wei Xu's most recent trade in NVE Corp was a trade of 1,000 Non-Qualified Stock Option done . Disclosure was reported to the exchange on Aug. 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NVE Corp | Xuan Kelly Wei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 1,000 | 2,000 | - | - | Non-Qualified Stock Option | |
| NVE Corp | Xuan Kelly Wei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 1,000 | 1,000 | - | - | Non-Qualified Stock Option | |
| GD Culture Group | Wei Xu | Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 256,000 | 387,340 | - | - | Common Stock | |
| GD Culture Group | Wei Xu | Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Jun 2022 | 93,333 | 294,007 | - | - | Common Stock | |
| CASI Pharmaceuticals Inc | Weihao Xu | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 800,000 | 800,000 | - | - | Employee Stock Option (Right to Buy) | |
| CASI Pharmaceuticals Inc | Weihao Xu | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.63 per share. | 16 Dec 2020 | 2,279 | 10,000 (0%) | 0% | 2.6 | 5,994 | Common Stock |
| CASI Pharmaceuticals Inc | Weihao Xu | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.44 per share. | 16 Dec 2020 | 2,000 | 6,000 (0%) | 0% | 2.4 | 4,880 | Common Stock |
| CASI Pharmaceuticals Inc | Weihao Xu | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.64 per share. | 16 Dec 2020 | 1,721 | 7,721 (0%) | 0% | 2.6 | 4,543 | Common Stock |